Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gongliuning tablets for uterine fibroids
ChiCTR1900021247Phase 4Not yet recruiting
- Sponsor
- Beijing Obstetrics and Gynecology Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Gongliuning tablets and mifepristone in Fibromyoma (LM) (3 arms), sponsored by Beijing Obstetrics and Gynecology Hospital. Primary endpoint: Uterus and fibroid size. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Gongliuning tabletsmifepristone
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on ChiCTR1900021247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021247.